Year: 2021
Type: review
Abstract: BACKGROUND: Over the past 20 years, insights from human and mouse genetics have illuminated the central role of the brain leptin-melanocortin pathway in controlling mammalian food intake, with genetic disruption resulting in extreme obesity, and more subtle polymorphic variations influencing the population distribution of body weight. At the end of 2020, the U.S. Food and Drug Administration (FDA) approved setmelanotide, a melanocortin 4 receptor agonist, for use in individuals with severe obesity due to either pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. SCOPE OF REVIEW: Herein, we chart the melanocortin pathway's history, explore its pharmacology, genetics, and physiology, and describe how a neuropeptidergic circuit became an important druggable obesity target. MAJOR CONCLUSIONS: Unravelling the genetics of the subset of severe obesity has revealed the importance of the melanocortin pathway in appetitive control; coupling this with studying the molecular pharmacology of compounds that bind melanocortin receptors has brought a new obesity drug to the market. This process provides a drug discovery template for complex disorders, which for setmelanotide took 25 years to transform from a single gene into an approved drug.
Source: Molecular Metabolism
Institutions: University of Cambridge, Wellcome/MRC Institute of Metabolic Science, Addenbrooke's Hospital, MRC Metabolic Diseases Unit, Centre National de la Recherche Scientifique, Université Paris Cité, Unit of Functional and Adaptive Biology, University of Minnesota, Monash University, University of Minnesota System, The University of Melbourne, Rhythm (United states), Inserm, Sorbonne Université, Nutrition et obésité : approches systémiques, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Utrecht University, University Medical Center Utrecht, University of Gothenburg
Language: English
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,100
Funders: European Commission, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Vetenskapsrådet, Centre National de la Recherche Scientifique, Université de Paris, National Institutes of Health, Medical Research Council, Biotechnology and Biological Sciences Research Council, National Health and Medical Research Council, Seventh Framework Programme, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: Young adults conceived with and without IVF, Targeting the neurons that drive overconsumption in obesity, Mechanisms in Disorders of Energy Balance, The Neurobiology of Decision-Making in Eating - Innovative Tools, G3711215709, Enabling technologies, Novel Melanocortin Receptor Probe Discovery, Mapping the human hypothalamic functional architecture underlying food intake control, NUTRIent Partitioning in Astrocyte and the regulation of energy HOmeoStasis, Can we engage weight loss circuits in the brain without causing hypertension?, Towards controlling the neurons driving overconsumption in obesity, G745319715, Molecular characterization in human neurons of genes associated with severe obesity identified from consanguineous pedigrees.
OpenAlex ID: W3134781470
